Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273795 | 1.00 | CYP1A2 (0.48) | CYP1A2CYP2D6CYP2C19HIF1AMAPT | |
| SCHEMBL3638061 | 0.89 | CYP2C19 (0.44) | CYP1A2CYP2D6CYP2C19HIF1AMAPT | |
| SCHEMBL2338585 | 0.87 | MAPT (0.53) | CYP1A2CYP2D6CYP2C19HIF1AMAPT | |
| SCHEMBL3862385 | 0.87 | CYP2C19 (0.43) | CYP1A2CYP2D6CYP2C19HIF1AMAPT | |
| SCHEMBL3953823 | 0.84 | KCNN4 (0.53) | CYP1A2CYP2D6CYP2C19HIF1AMAPT | |
| SCHEMBL4001665 | 0.83 | CYP2D6 (0.44) | CYP1A2CYP2D6CYP2C19HIF1AMAPT | |
| SCHEMBL4003586 | 0.83 | CYP2D6 (0.44) | CYP1A2CYP2D6CYP2C19HIF1AMAPT | |
| SCHEMBL3953264 | 0.83 | CYP2D6 (0.44) | CYP1A2CYP2D6CYP2C19HIF1AMAPT | |
| SCHEMBL11415156 | 0.81 | MMP8 (0.46) | MAPTKMT2ASMN1; SMN2GRIN2DGRIN1 | |
| SCHEMBL28564931 | 0.80 | CYP2D6 (0.48) | CYP1A2CYP2D6CYP2C19HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 614 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719194-A1 | METHODS FOR INCORPORATING THERAPEUTIC AGENTS INTO ANALYTE SENSORS | Abbott Diabetes Care, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4642438-A1 | DRUG DELIVERY COMPOSITIONS AND METHODS OF CONTROLLING DRUG DELIVERY RATES OF SUBCUTANEOUS SENSORS | Abbott Diabetes Care Inc. (US) | 2025-11-05 | — | — | EP | claimed |
| EP-3840637-B1 | MEDIATED DRUG RELEASE FOR REDUCING IN VIVO ANALYTE INDICATOR DEGRADATION | SENSEONICS INC (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4590371-A2 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | Scientific Horizons consulting LLC (US) | 2025-07-30 | — | — | EP | claimed |
| US-20240423511-A1 | METHODS FOR INCORPORATING THERAPEUTIC AGENTS INTO ANALYTE SENSORS | ABBOTT DIABETES CARE INC. (US) | 2024-12-26 | — | — | US | claimed |
| WO-2024243577-A1 | METHODS FOR INCORPORATING THERAPEUTIC AGENTS INTO ANALYTE SENSORS | ABBOTT DIABETES CARE INC. (US) | 2024-11-28 | — | — | WO | claimed |
| US-20240216589-A1 | DRUG DELIVERY COMPOSITIONS AND METHODS OF CONTROLLING DRUG DELIVERY RATES OF SUBCUTANEOUS SENSORS | ABBOTT DIABETIS CARE INC. (US) | 2024-07-04 | — | — | US | claimed |
| WO-2024145693-A1 | DRUG DELIVERY COMPOSITIONS AND METHODS OF CONTROLLING DRUG DELIVERY RATES OF SUBCUTANEOUS SENSORS | ABBOTT DIABETES CARE INC. (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2024064885-A2 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2024-03-28 | — | — | WO | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| CN-1625411-A | Combination of a NSAID and a PDE-4 inhibitor | ALTANA PHARMA AG (DE) | 2005-06-08 | — | — | CN | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-5855915-A | COMPLEX OF ASPIRIN AND POLYGLYCOLIDE | BAYLOR UNIVERSITY (US) | 1999-01-05 | — | — | US | claimed |
| US-5833715-A | Implantable stimulation lead having an advanceable therapeutic drug delivery system | PACESETTER, INC. (US) | 1998-11-10 | — | — | US | claimed |
| WO-1997002019-A1 | POLYESTER/CARBOXYLIC ACID COMPOSITE MATERIALS | BAYLOR UNIVERSITY (US) | 1997-01-23 | — | — | WO | claimed |
| US-5531780-A | Implantable stimulation lead having an advanceable therapeutic drug delivery system | PACESETTER, INC. (US) | 1996-07-02 | — | — | US | claimed |
| EP-0428352-B1 | Anti-inflammatory compositions for external use | BETA PHARM CO (UY) | 1995-08-09 | — | — | EP | claimed |
| EP-0428352-A1 | Anti-inflammatory compositions for external use | Beta Pharmaceuticals Co. (UY) | 1991-05-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | CYP1A2 1066/4885CYP2D6 1222/4885CYP2C19 1490/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | CYP1A2 968/4885CYP2D6 1122/4885CYP2C19 1364/4885 |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | TMCO1, TANK, SARAF | CYP1A2 370/4885CYP2D6 1791/4885CYP2C19 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.